Filtered By:
Cancer: Breast Cancer
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 2131 results found since Jan 2013.
LncRNA AGPG confers endocrine resistance in breast cancer by promoting E2F1 activity
Cancer Res. 2023 Jul 18:CAN-23-0015. doi: 10.1158/0008-5472.CAN-23-0015. Online ahead of print.ABSTRACTResistance to endocrine therapy represents a major concern for patients with estrogen receptor α positive (ERα+) breast cancer. Endocrine therapy resistance is commonly mediated by activated E2F signaling. A better understanding of the mechanisms governing E2F1 activity in resistant cells could reveal strategies for overcoming resistance. Here, we identified the long non-coding RNA (lncRNA) actin gamma 1 pseudogene 25 (AGPG) as a regulator of E2F1 activity in endocrine resistant breast cancer. Expression of EGPG was inc...
Source: Cell Research - July 18, 2023 Category: Cytology Authors: Shiyi Yu Ying Wang Xue Gong Zhehao Fan Zheng Wang Zhengyan Liang Rui Wu Binjie Cao Ning Wang Caili Bi Dan Lv Haibo Sun Source Type: research
Simvastatin prevents BMP-2 driven cell migration and invasion by suppressing oncogenic DNMT1 expression in breast cancer cells
This study emphasized to decipher the molecular mechanism of endogenous regulation of DNMT1 expression for finding upstream signaling molecules. Cancer database analyses found an upregulated DNMT1 expression in most cancer types including breast cancer. Overexpression of DNMT1 showed an increased cell migration, invasion, and stemness potential whereas 5-azacytidine (DNMT1 inhibitor) and siRNA mediated knockdown of DNMT1 exhibited inhibition of such cancer activities in breast cancer MDA-MB-231 and MCF-7 cells. Infact, cancer database analyses further found a positive correlation of DNMT1 transcript with both cholesterol p...
Source: Gene - July 13, 2023 Category: Genetics & Stem Cells Authors: Pooja Yadav Shreetama Bandyopadhayaya Sneha Soni Sunil Saini Lokendra K Sharma Sandeep K Shrivastava Chandi C Manda Source Type: research
Simultaneous Delivery of Doxorubicin and EZH2 ‐Targeting siRNA by Vortex Magnetic Nanorods Synergistically Improved Anti‐Tumor Efficacy in Triple‐Negative Breast Cancer
A novel nanomedicine is synthesized based on Fe3O4 vortex nanorods loaded with doxorubicin (DOX) and EZH2 siRNAs and coated with a macrophage membrane. It shows a preferential tumor enrichment profile, thus leading to highly efficient drug delivery at the tumor site. Combining chemotherapy and gene therapy exhibits synergistic antitumor activity in a preclinical TNBC model. AbstractTriple-negative breast cancer (TNBC), one of the most aggressive types of breast cancer, currently lacks a targeted therapy and has a high clinical recurrence rate. The present study reports an engineered magnetic nanodrug based on Fe3O4 vortex ...
Source: Small - June 28, 2023 Category: Nanotechnology Authors: Yunshu Lu,
Fenfen Gu,
Yuwei Ma,
Ruonan Li,
Yi Luo,
Xianhong Da,
Lan Jiang,
Xiang Li,
Yan Liu Tags: Research Article Source Type: research
DDIT4 Downregulation by siRNA Approach Increases the Activity of Proteins Regulating Fatty Acid Metabolism upon Aspirin Treatment in Human Breast Cancer Cells
Curr Issues Mol Biol. 2023 May 28;45(6):4665-4674. doi: 10.3390/cimb45060296.ABSTRACTRepositioning of aspirin for a more effective breast cancer (BC) treatment requires identification of predictive biomarkers. However, the molecular mechanism underlying the anticancer activity of aspirin remains fully undefined. Cancer cells enhance de novo fatty acid (FA) synthesis and FA oxidation to maintain a malignant phenotype, and the mechanistic target of rapamycin (mTORC1) is required for lipogenesis. We, therefore, aimed to test if the expression of mTORC1 suppressor DNA damage-inducible transcript (DDIT4) affects the activity of...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Aist ė Savukaitytė Agn ė Bartnykaitė Justina Bekampyt ė Rasa Ugenskien ė Elona Juozaityt ė Source Type: research
